Synaptic proteins in CSF relate to Parkinson’s disease stage markers
Open accessAbstract
Recent findings of morphological and functional changes in Parkinson’s disease brains have shown altered synapse formation, but their role in cognitive decline is still an area under exploration. Here we measured the concentration of three key synaptic proteins, Rab3A, SNAP25 and neurogranin by enzyme-linked immunosorbent assay, in cerebrospinal fluid from a total of 139 participants (87 controls and 52 Parkinson’s disease patients out of which 30 were drug-naïve) and explored their associations with motor and cognitive symptoms. Associations with motor disease stage (assessed by Hoehn and Yahr scale) and cognitive performance (assessed by the Montreal Cognitive Assessment scores) were explored. An overall increase in the concentration of SNAP25 was found in Parkinson’s disease patients (p = 0.032). Increased neurogranin levels were found in the drug naïve patients subgroup (p = 0.023). Significant associations were observed between increased concentration of neurogranin and cognitive impairment in total Parkinson’s disease group (p = 0.017), as well as in the drug naïve (p = 0.021) and with motor disease stage (p = 0.041). There were no significant disease-driven changes observed in the concentration of Rab3a. Concentrations SNAP25 and neurogranin were increased in cerebrospinal fluid of Parkinson’s disease patients in a disease specific manner and related to cognitive and motor symptom severity. Future longitudinal studies should explore whether cerebrospinal fluid synaptic proteins can predict cognitive decline in Parkinson’s disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Synaptic dysfunction contributes to disease pathogenesis in PD and may be linked to cognitive and motor dysfunction.
“Synaptic dysfunction contributes to disease pathogenesis in PD (Nguyen et al. 2019) and may be linked to cognitive and motor dysfunction (Bereczki et al. 2017; Moran et al. 2008).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Bereczki et al. 2017
In later stages, aggregation with misfolded proteins in tissue and widespread neurodegeneration would explain reduced CSF values.
“whereas in later stages, the aggregation with misfolded proteins in the tissue (Bereczki et al. 2017) and the confounded widespread neurodegeneration would explain the reduced CSF values.”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Bereczki et al. 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · see citing works
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219 · see citing works
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · see citing works
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · see citing works
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824 · see citing works
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb06891.x · Cited by 811 · see citing works
Self-citationSynaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.
Hayashi, T., McMahon, H. T., Yamasaki, S., Binz, T., Hata, Y., Südhof, T. C., & Niemann, H. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06834.x · Cited by 798 · see citing works
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 541 · see citing works
Goldberg, M. S., Pisani, A., Haburčák, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 532 · see citing works
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C. G., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 497 · see citing works
Self-citationMollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works
Gispert, S., Ricciardi, F., Kurz, A., Azizov, M., Hoepken, H.-H., Becker, D., Voos, W., Leuner, K., Müller, W. E., Kudin, A. P., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005777 · Cited by 382 · see citing works
Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · see citing works
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279 · see citing works
Baudier, J., Deloulme, J., DORSSELAER, A. V., Black, D. M., & Matthes, H. W. D. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52425-x · Cited by 274 · see citing works
LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool
Piccoli, G., Condliffe, S. B., Bauer, M., Giesert, F., Boldt, K., Astis, S. D., Meixner, A., Sarioglu, H., Weisenhorn, D. M. V., Wurst, W., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3730-10.2011 · Cited by 267 · see citing works
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · see citing works
Alves, G. W., Brønnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C. G., Kurz, M. W., Andréasson, U., Tysnes, O., Larsen, J. O., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221 · see citing works
Self-citationNeurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.073 · Cited by 204 · see citing works
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in L ewy Body Dementias
Howlett, D. R., Whitfield, D., Johnson, M. A., Attems, J., O'Brien, J. T., Aarsland, D., Lai, M. K. P., Lee, J. H., Chen, C., Ballard, C. G., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12182 · Cited by 196 · see citing works
Self-citationSynaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Höglund, K., Bogstedt, A., Cedazo‐Minguez, A., Baek, J., Hortobágyi, T., Attems, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.005 · Cited by 167 · see citing works
Self-citationCognitive impairment in Parkinson's disease and dementia with Lewy bodies
Aarsland, D. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.034 · Cited by 145 · see citing works
Self-citationWhitfield, D., Vallortigara, J., Alghamdi, A., Howlett, D. R., Hortobágyi, T., Johnson, M., Attems, J., Newhouse, S., Ballard, C. G., Thomas, A. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.015 · Cited by 141 · see citing works
Self-citationMild cognitive impairment in Parkinson's disease
Yarnall, A. J., Rochester, L., & Burn, D. J. (2013) · Age and Ageing · doi:10.1093/ageing/aft085 · Cited by 118 · see citing works
Björkhem, I., Lövgren‐Sandblom, A., Leoni, V., Meaney, S., Brodin, L., Salveson, L., Winge, K., Pålhagen, S., & Svenningsson, P. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.003 · Cited by 112 · see citing works
Self-citationAbnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease
Dalfó, E., Barrachina, M., Rosa, J. L., Ambrosio, S., & Ferrer, I. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.001 · Cited by 94 · see citing works
Neuronal activity drives matching of pre- and postsynaptic function during synapse maturation
Kay, L., Humphreys, L., Eickholt, B. J., & Burrone, J. (2011) · Nature Neuroscience · doi:10.1038/nn.2826 · Cited by 41 · see citing works
Molecular biomarkers of neurodegeneration
Höglund, K., & Salter, H. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.850033 · Cited by 33 · see citing works
Self-citationVallortigara, J., Rangarajan, S., Whitfield, D., Alghamdi, A. A., Howlett, D. R., Hortobágyi, T., Johnson, M. A., Attems, J., Ballard, C. G., Thomas, A. J., et al. (2014) · F1000Research · doi:10.12688/f1000research.3786.1 · Cited by 25 · see citing works
Self-citationP2‐123: BIOMARKERS FOR COGNITIVE DECLINE OF EARLY PARKINSON's DISEASE
Bereczki, E., Höglund, K., Svenningsson, P., Cedazo-Mı́nguez, Á., Francis, P. T., Ballard, C. G., & Aarsland, D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.798 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027 · see citing works
Self-citationSynaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D. (2018) · Brain · doi:10.1093/brain/awx352 · Cited by 220 · see citing works
Self-citationFluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works
Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease
Wang, S., Kojima, K., Mobley, J. A., & West, A. B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.021 · Cited by 145 · see citing works
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works
Fluid markers of synapse degeneration in synucleinopathies
Cervantes González, A., & Belbin, O. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02467-8 · Cited by 7 · see citing works
- Authors
- Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D.
- Affiliations
- Karolinska Institutet (SE)
- Sahlgrenska University Hospital (SE)
- University of Exeter (GB)
- Corresponding author
- Bereczki, Erika
- Venue
- npj Parkinson's Disease
- Published
- 2017-02-08
- Volume
- 3
- Issue
- 1
- Pages
- 7-7
- ISSN
- 2373-8057 (ISSN-L)
- PMC
- PMC5445607
- OpenAlex
- W2582951843
- Cited by
- 72
- References
- 33
- Citations by year
- 2025: 10 · 2024: 13 · 2023: 8 · 2022: 9 · 2021: 6 · 2020: 10 · 2019: 6 · 2018: 6 · 2017: 4
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- npj Parkinson s Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gun och Bertil Stohnes Stiftelse
- Alzheimerfonden
- Demensfonden
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Parkinson's disease, synaptic proteins, cerebrospinal fluid biomarkers, Rab3A, SNAP-25, neurogranin, cognitive impairment, Hoehn and Yahr stage, Montreal Cognitive Assessment, drug-naive patients, synaptogenesis, cognitive decline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
